Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J. +18 more·2016·Nature Communications

DOI 10.1038/ncomms10501

Cited by (1,000)

Items 501–600 of 1,000

T-cell exhaustion in glioblastoma
Karolina I. Woroniecka, Peter Edward Fecci · 2018 · Oncotarget
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
Naiyer A. Rizvi, Foluso Olabisi Ademuyiwa, Zhu Alexander Cao, Helen X. Chen, Robert Louis Ferris, Sarah B. Goldberg, Matthew David Hellmann, Ranee Mehra, Ina Park Rhee, Jong Chul Park et al. · 2023 · Journal for ImmunoTherapy of Cancer
Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma
Daniel Y. Wang, Zeynep Eroglu, Alpaslan Özgün, Paul Denis Leger, Shilin Zhao, Fei Ye, Jason J. Luke, Richard Wayne Joseph, Rizwan Haq, Patrick Alexander Ott et al. · 2017 · Cancer Immunology Research
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
Ugo Testa, Germana Castelli, Elvira Pelosi · 2017 · Medical Sciences
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma
Maria Rita Gaiser, Michelle A. Bongiorno, Isaac Brownell · 2018 · Expert Review of Clinical Pharmacology
PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis
Shwetank, Elizabeth L. Frost, Taryn E. Mockus, Heather M. Ren, Mesut Toprak, Matthew D. Lauver, Colleen S. Netherby, Ge Jin, Jennifer Cosby, Brian D. Evavold et al. · 2019 · Frontiers in Immunology
Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor
Flavia Fontana, Manlio Fusciello, Christianne Groeneveldt, Cristian Capasso, Jacopo Chiaro, Sara Feola, Zehua Liu, Ermei M. Mäkilä, Jarno Salonen, Jouni J. Hirvonen et al. · 2019 · ACS Nano
Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
Yuan Zhuang, Chang Xin Liu, Jiaqing Liu, Guang Li · 2020 · OncoTargets and Therapy
Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Xue-lin Zou, Xiaobo Li, Hua Ke, Guangyan Zhang, Qing Tang, Jiao Yuan, Chen-jiao Zhou, Jiliang Zhang, Rui Zhang, Wei-yong Chen · 2021 · Frontiers in Immunology
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells
Yanyun Du, Qianwen Peng, Du Cheng, Ting Shuang Pan, Wanwei Sun, Heping Wang, Xiaojian Ma, Rui-Rui He, Huazhi Zhang, Zhihui Cui et al. · 2022 · Nature Communications
CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1
Beiping Miao, Zhaoqing Hu, Riccardo Mezzadra, Lotte L. Hoeijmakers, Astrid Fauster, Shangce Du, Zhi Yang, Melanie Sator‐Schmitt, Helena Engel, Xueshen Li et al. · 2023 · Cancer Cell
Prostate cancer immunotherapy
Marco Antonio De Velasco, Hirotsugu Uemura · 2017 · Current Opinion in Urology
HisgAtlas 1.0: a human immunosuppression gene database
Yuan Liu, Mengqi He, Dan Wang, Lihong Diao, Jinying Liu, Tang Li, Shuzhen Guo, Fuchu He, Dong Li · 2017 · Database
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
MacLean S. Hall, John E. Mullinax, Cheryl A. Cox, Amy M. Hall, Matthew S. Beatty, Jamie L. Blauvelt, Patrick Innamarato, Luz Nagle, Holly Branthoover, Doris A. Wiener et al. · 2022 · Clinical Cancer Research
Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Merve Hazal Ser, Mason Webb, Ugur T. Sener, Jian Li Campian · 2023 · Journal of Immunotherapy and Precision Oncology
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Daniel S. Lefler, Steven Anthony Manobianco, Babar Bashir · 2024 · Cancer Biology & Therapy
Check point inhibitors as therapies for infectious diseases
Maureen A. Cox, Robert Nechanitzky, Tak W. Mak · 2017 · Current Opinion in Immunology
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Gao Zhang, Lawrence Wen Wu, Ilgen Mender, Michal Barzily-Rokni, Marc R. Hammond, Omotayo Ope, Chaoran Cheng, Themistoklis Vasilopoulos, Sergio Randell, Norah Layla Sadek et al. · 2018 · Clinical Cancer Research
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma
Yuka Kozuma, Kazuki Takada, Gouji Toyokawa, Kenichi Kohashi, Mototsugu Shimokawa, Fumihiko Hirai, Tetsuzo Tagawa, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara · 2018 · European Journal of Cancer
Identification and characterization of M6903, an antagonistic anti–TIM-3 monoclonal antibody
Dong Zhang, Feng Jiang, Rinat Zaynagetdinov, Hui Huang, Vanita D. Sood, Hong Wang, Xinyan Zhao, Molly H. Jenkins, Qingyong Ji, Youbin Wang et al. · 2020 · OncoImmunology
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
Jan Philipp Bewersdorf, Rory Michael Shallis, Amer Methqal Zeidan · 2020 · Blood Reviews
Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Yolla Haibe, Ziad El Husseini, Rola El Sayed, Ali I. Shamseddine · 2020 · International Journal of Molecular Sciences
Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise, Daniel Olive · 2020 · Journal of Leukocyte Biology
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Ranjan Pathak, Rebecca R. Pharaon, Atish Ranjan Mohanty, Victoria Meucci Villaflor, Ravi Salgia, Erminia Massarelli · 2020 · Cancers
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
Veronica Olivo Pimentel, Damiënne Marcus, Alexander Marie-Madeleine Adrianus van der Wiel, Natasja G. Lieuwes, Rianne Biemans, Relinde I. Y. Lieverse, Dario Neri, Jan Theys, Ala Yaromina, Ludwig Jerome Dubois et al. · 2021 · Journal for ImmunoTherapy of Cancer
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
Iris H.C. Miedema, Marc C. Huisman, Gerben J.C. Zwezerijnen, Rolf Grempler, Alejandro Pérez Pitarch, Andrea Thiele, Raphael Hesse, Mabrouk M. Elgadi, Alexander Peltzer, Daniëlle J. Vugts et al. · 2023 · European Journal of Nuclear Medicine and Molecular Imaging
PD-L1 IHC in NSCLC with a global and methodological perspective
Erik Thunnissen, Adrianus Johannes de Langen, Egbert Frederik Smit · 2017 · Lung Cancer
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
Valentina Rigo, Laura Emionite, Antonio Daga, Simonetta Astigiano, Maria Valeria Corrias, Concetta Quintarelli, Franco Locatelli, Silvano Ferrini, Michela Croce · 2017 · Scientific Reports
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer
Keyi Jia, Yayi He, Rafał Dziadziuszko, Sha Zhao, Xiaoshen Zhang, Juan Deng, Hao Wang, Fred R. Hirsch, Caicun Zhou, Hui Yu et al. · 2019 · Translational Lung Cancer Research
Immunotherapy in Multiple Myeloma
Cinnie Yentia Soekojo, Melissa Gaik Ming Ooi, Sanjay De Mel, Wee Joo Chng · 2020 · Cells
Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy
Junhao Li, Lujia Huang, Huiling Zhou, Yi-ming Shan, Fangmin Chen, Vesa‐Pekka Lehto, Wujun Xu, Liqiang Luo, Haijun Yu · 2022 · Acta Pharmacologica Sinica
Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer
Melani Luque, Marta Sanz-Álvarez, Miriam Morales-Gallego, Juan Madoz‐Gúrpide, Sandra Zazo, Carolina Domínguez, Alicia Cazorla, Yann Izarzugaza, Juan Luis Arranz, Ion Cristóbal et al. · 2022 · Cancers
In Situ STING‐Activating Nanovaccination with TIGIT Blockade for Enhanced Immunotherapy of Anti‐PD‐1‐Resistant Tumors
Beibei Zhang, Juan Zhang, Yaqiong Li, Na Li, Yuzhou Wang, Ru Jang, Xiaoxia Xu, Ruifang Li, Zhenzhen Chen, Shaobo Duan et al. · 2023 · Advanced Materials
Novel immune checkpoint targets: A promising therapy for cancer treatments
Mohsina F. Patwekar, Nouroz Sehar, Faheem Patwekar, Anuradha Medikeri, Shafat Ali, Rana M Aldossri, Muneeb U. Rehman · 2023 · International Immunopharmacology
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas
Farah Succaria, Pia Kvistborg, Julie E. Stein, Elizabeth L. Engle, Tracee L. McMiller, Lisa M. Rooper, Elizabeth D. Thompson, Alan E. Berger, Michiel W. M. van den Brekel, Charlotte L. Zuur et al. · 2020 · Cancer Immunology Immunotherapy
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Qingyi Wang, Bin Xie, Shuang Liu, Ying Shi, Yongguang Tao, Desheng Xiao, Wenxiang Wang · 2021 · Frontiers in Immunology
Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non–small cell lung cancer
Qingyuan Huang, Fei Li, Hai Hu, Zhaoyuan Fang, Zhendong Gao, Guozhan Xia, Wai‐Lung Ng, Alireza Khodadadi‐Jamayran, Ting Chen, Jiehui Deng et al. · 2022 · Science Advances
Cancer Stem Cell markers: Symphonic masters of chemoresistance and immune evasion
Miguel Ángel Sarabia-Sánchez, José Manuel Tinajero-Rodríguez, Elizabeth Ortíz-Sánchez, Eduardo Alvarado-Ortiz · 2024 · Life Sciences
Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection
John J. Erickson, Meredith C. Rogers, Sharon J. Tollefson, Kelli Lynn Boyd, John V. Williams · 2016 · The Journal of Immunology
Recent Advances in Immunotherapy in Metastatic NSCLC
Pranshu Bansal, Diaa I. Osman, Gregory N. Gan, George R. Simon, Yanis Boumber · 2016 · Frontiers in Oncology
Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer
Russell William Jenkins, Rohit Thummalapalli, Jacob Carter, Israel Cañadas, David Allen Barbie · 2017 · Annual Review of Medicine
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
Minfeng Yang, In Young Oh, Arpan Mahanty, Weilin Jin, Jung Sun Yoo · 2020 · Cancers
Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells
Yizi Cong, Yuxin Cui, Shiguang Zhu, Jianqiao Cao, Haidong Zou, Tracey Amanda Martin, Guangdong Qiao, Wen G. Jiang, Zhigang Yu · 2020 · Chinese Journal of Cancer Research
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
Chen Chen, Yanlong Liu, Binbin Cui · 2021 · Human Vaccines & Immunotherapeutics
In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment
Stefan Grote, Guillermo Ureña-Bailén, Kenneth Chun-Ho Chan, Caroline Baden, Markus Mezger, Rupert Handgretinger, Sabine Schleicher · 2021 · Cells
Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
Xunrui Chen, Wenhui Zhang, Wenyan Yang, Min Zhou, Feng Liu · 2022 · Aging
Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
Kostas Palamaris, Myrto K. Moutafi, Hariklia Gakiopoulou, Stamatios E Theocharis · 2022 · International Journal of Molecular Sciences
Modelling the tumor immune microenvironment for precision immunotherapy
Nathan J. Mackenzie, Clarissa Nicholls, Abby R. Templeton, Omattage Mahasha Perera, Penny L. Jeffery, Kate Zimmermann, Arutha Kulasinghe, Tony Kenna, Ian Vela, Elizabeth D. Williams et al. · 2022 · Clinical & Translational Immunology
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Yong-Qiang Ao, Jian Gao, Shuai Wang, Jia-Hao Jiang, Jie Deng, Haikun Wang, Bei Xu, Jian‐Yong Ding · 2023 · Molecular Cancer
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Wenyue Sun, Shunfeng Hu, Xin Wang · 2024 · 癌症：英文版
Impaired functional responses in follicular lymphoma CD8+TIM-3+T lymphocytes following TCR engagement
Pauline Gravelle, Catherine Do, Camille Franchet, Sabina Müller, Lucie Obéric, Loïc Ysebaert, Luigi Maria Larocca, Stefan Hohaus, M. Calmels, François-Xavier Frénois et al. · 2016 · OncoImmunology
Long non‐coding RNA AGER‐1 functionally upregulates the innate immunity gene AGER and approximates its anti‐tumor effect in lung cancer
Zihua Pan, Li Liu, Wenjing Nie, Sinéad M. Miggin, Fuman Qiu, Yi Cao, Jinbin Chen, Binyao Yang, Yifeng Zhou, Jiachun Lü et al. · 2017 · Molecular Carcinogenesis
Immunogenic cell death-inducing chemotherapeutic nanoformulations potentiate combination chemoimmunotherapy
Jianhua Liu, Zhongmin Li, Duoyi Zhao, Xiangru Feng, Chunxi Wang, Di Li, Jianxun Ding · 2021 · Materials & Design
Breast cancer resistance mechanisms: challenges to immunotherapy
Ann Hanna, Justin Micah Balko · 2021 · Breast Cancer Research and Treatment
Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy
Yuanji Feng, Jiayan Wu, Jie Chen, Lin Lın, Sijia Zhang, Zhiyu Yang, Pingjie Sun, Yanhui Li, Huayu Tian, Xuesi Chen · 2021 · Nano Today
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment
Grazia Raffaella Tundo, Diego Sbardella, Pedro Miguel Lacal, Grazia Graziani, Stefano Marini · 2019 · Chemotherapy
In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti–PD-1/PD-L1 Therapies
Morgane Denis, Chloé Grasselly, Pierre‐Antoine Choffour, Anne Wierinckx, Doriane Mathé, Kamel Chettab, Anne Tourette, Nolan Talhi, Aurore Bourguignon, Fabian Birzele et al. · 2022 · Cancer Immunology Research
The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy
Katarzyna Starska · 2023 · Cancers
Novel Microwave Torso Scanner for Thoracic Fluid Accumulation Diagnosis and Monitoring
Sasan Ahdi Rezaeieh, Ali Zamani, Konstanty S. Bialkowski, Amin M Abbosh · 2017 · Scientific Reports
Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy
Ying-Ying Li, Lynn G. Feun, Angkana Thongkum, Chiao-Hui Tu, Shu-Mei Chen, Medhi Wangpaichitr, Chunjing Wu, Macus Tien Kuo, Niramol Savaraj · 2017 · International Journal of Molecular Sciences
Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia
Saeid Taghiloo, Esmaeil Allahmoradi, Reza Ebadi, Mohsen Tehrani, Zahra Hosseini‐khah, Ghasem Janbabaei, Ramin Shekarriz, Hossein Asgarian‐Omran · 2017 · PubMed Central
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
Astrid Holzinger, Hinrich Abken · 2019 · HemaSphere
Intrinsic cancer vaccination
Yoosoo Yang, Gi‐Hoon Nam, Gi Beom Kim, Yoon Kyoung Kim, In‐San Kim · 2019 · Advanced Drug Delivery Reviews
Transposon-mediated generation of CAR-T cells shows efficient anti B-cell leukemia response after ex vivo expansion
Leonardo Chicaybam, Luiza de Macedo Abdo, Mariana Saldanha Viegas, Luísa Vieira Codeço Marques, Priscila de Sousa, Leonardo Ribeiro Batista-Silva, Viviane Alves-Monteiro, Simone T. Bonecker, Bárbara da Costa Reis Monte-Mór, Martín Bonamino · 2020 · Gene Therapy
Hyperprogression: A novel response pattern under immunotherapy
Xuejiao Han, Aqu Alu, Yinan Xiao, Yu‐quan Wei, Xia‐wei Wei · 2020 · Clinical and Translational Medicine
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
Allan Relecom, Maysaloun Merhi, Varghese Philipose Inchakalody, Shahab Uddin M.S., Darawan Rinchai, Davide Bedognetti, Said Dermime · 2021 · Journal of Experimental & Clinical Cancer Research
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy
Marie Bernardo, Tatiana Tolstykh, Yuan Zhang, Dinesh S. Bangari, Hui Cao, Kerstin A. Heyl, Joon Sang Lee, Natalia V. Malkova, Katie Malley, Eladio J. Márquez et al. · 2021 · OncoImmunology
Networks of CD8+ T Cell Response Activation in Melanoma and Vitiligo
Keitaro Fukuda · 2022 · Frontiers in Immunology
A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival
Tolga Turan, Sarah Kongpachith, Kyle D. Halliwill, Jessica P Roelands, Wouter Hendrickx, Francesco Maria Marincola, Thomas J. Hudson, Howard J. Jacob, Davide Bedognetti, Josue A. Samayoa et al. · 2020 · British Journal of Cancer
Personalized medicine: From diagnostic to adaptive
Zachary V. Braig · 2019 · Biomedical Journal
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?
Chin Sern Yiong, Tzu Ping Lin, Vivian Lim, Tan Boon Toh, Valerie Shiwen Yang · 2023 · Biomarker Research
Checks and Balances in Autoimmune Vasculitis
Rebeca Hid Cadena, Wayel Habib Abdulahad, Geke A.P. Hospers, Thijs T. Wind, Annemieke M. H. Boots, Peter Heeringa, Elisabeth Brouwer · 2018 · Frontiers in Immunology
TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers
Margaret E. Moore, Kari Lassen Ring, Anne M. Mills · 2019 · Modern Pathology
Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
Ji‐Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung · 2020 · International Journal of Molecular Sciences
Long non-coding RNAs: Emerging regulators for chemo/immunotherapy resistance in cancer stem cells
Chongyang Shen, Chuan He Yang, Bing Xia, Ming You · 2020 · Cancer Letters
The role of LncRNAs in tumor immunotherapy
Xuan Pan, Chenchen Li, Jifeng Feng · 2023 · Cancer Cell International
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Xin Su, Jian Li, Xiao Xu, Youbao Ye, Cailiu Wang, Guanglong Pang, Wenxiu Liu, Ang Liu, Changchun Zhao, Xiangyong Hao · 2024 · Journal of Translational Medicine
Immunotherapeutic strategies in head and neck cancer: challenges and opportunities
Xia Liu, R. Alex Harbison, Mark Alex Varvares, Sidharth V. Puram, Guangyong Peng · 2025 · Journal of Clinical Investigation
Immune checkpoint blockade combined with IL ‐6 and TGF ‐β inhibition improves the therapeutic outcome of m RNA ‐based immunotherapy
Lukasz Bialkowski, Kevin Van der Jeught, Sanne Bevers, Patrick Tjok Joe, Dries Renmans, Carlo Heirman, Joeri L. Aerts, Kris Thielemans · 2018 · International Journal of Cancer
Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Jarem J. Edwards, Annie T. Tasker, Inês Pires da Silva, Camelia Y. J. Quek, Marcel Batten, Angela L. Ferguson, Ruth O. Allen, Benjamin Michael Allanson, Robyn P.M. Saw, John F. Thompson et al. · 2019 · Clinical Cancer Research
Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients
Kangni Wu, Juan Feng, Yanghui Xiu, Zhifeng Li, Zhijuan Lin, Haijun Zhao, Hanyan Zeng, Weilin Xia, Lian Yu, Bing Xu · 2020 · International Immunopharmacology
The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers
Geng Wang, Risheng Tai, Yanshuang Wu, Shanru Yang, Jingjing Wang, Xiaolan Yu, Lei Lei, Zhiyan Shan, Na Li · 2020 · Cytokine & Growth Factor Reviews
Mechanisms of Resistance to Checkpoint Blockade Therapy
Hubing Shi, Jiang Lan, Jiqiao Yang · 2020 · Advances in experimental medicine and biology
Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
Lili Huang, Yu Xu, Juemin Fang, Weixing Liu, Jianhua Chen, Zhuqing Liu, Qing Xu · 2021 · Frontiers in Immunology
Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells
Leila Jafarzadeh, Elham Masoumi, Hamid Reza Mirzaei, Khadijeh Alishah, Keyvan Fallah-Mehrjardi, Mohammad Khakpoor-Koosheh, Hosein Rostamian, Farshid Noorbakhsh, Jamshid Hadjati · 2021 · Molecular Immunology
Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)
Oula El Atat, Rayan Naser, Maya Abdelkhalek, Ralph Joseph Abi‐Habib, Mirvat El‐Sibai · 2022 · Oncology Letters
Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation
Hongmu Li, Miao Yu, Leqi Zhong, Songjie Feng, Yue Xu, Lu Tang, Chun Jing Wu, Xianzhou Zhang, Ling Gu, Hengyi Diao et al. · 2023 · Frontiers in Immunology
Functional status and spatial architecture of tumor-infiltrating CD8+ T cells are associated with lymph node metastases in non-small cell lung cancer
Guanqun Yang, Siqi Cai, Mengyu Hu, Chaozhuo Li, Liying Yang, Wei Zhang, Jujie Sun, Fenghao Sun, Ligang Xing, Xiaorong Sun · 2023 · Journal of Translational Medicine
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo, Jixia Li, Jinxia Hu, Qiang Fu, Yunfei Yan, Sen Xu, Xin Wang, Fei Jiao · 2023 · International Immunopharmacology
High-dimensional multi-pass flow cytometry via spectrally encoded cellular barcoding
Sheldon J. J. Kwok, Sarah Forward, Marissa D. Fahlberg, Emane Rose Assita, Sean Cosgriff, Seung Hyung Lee, Geoffrey R. Abbott, Han Zhu, Nicolas H. Minasian, A. Sean Vote et al. · 2023 · Nature Biomedical Engineering
Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications
Jie Wang, Yian Wang, Xianjie Jiang, Meifang Xu, Meifeng Wang, Rong Wang, Boshu Zheng, Mingfen Chen, Ke Qi, Jun Long · 2024 · Cancer Letters
The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Jie Zhang, Longsheng Wang, Hongjie Guo, Shijia Kong, Wen Li, Qiaojun He, Ling Ding, Bo Yang · 2024 · Pharmacological Research
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer · 2017 · Cell Communication and Signaling
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects
Long Long, Chen Zhao, Ozarina Muqimova, Xianda Zhao, Jing Liang Yang, Honglei Chen · 2019 · Clinical Drug Investigation
Expression of costimulatory and inhibitory receptors in FoxP3+ regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches
Aras Toker, Pamela S. Ohashi · 2019 · Advances in cancer research
Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways
Bingjian Wen, Chengcheng Zhang, Jingwen Zhou, Zhengyan Zhang, Qishi Che, Hua Cao, Yan Bai, Jiao Guo, Zhengquan Su · 2020 · Pharmacology & Therapeutics
Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy
Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang, Xia Zhao · 2021 · Frontiers in Cell and Developmental Biology
CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
Asa P. Y. Lau, Sharon S. Khavkine Binstock, Kelsie L. Thu · 2023 · Cancers
Resistance to immune checkpoint inhibitors in gastric cancer
Kai Liu, Shiman Yuan, Chenyu Wang, Hong Zhu · 2023 · Frontiers in Pharmacology
Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics
Ziyang Ye, Genpeng Li, Jianyong Lei · 2024 · Experimental & Molecular Medicine